Biotech — XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease with secondary programs focused on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
Learn more at
1 403 607-2621
Led by Chartered Investment Manager, Greg Beckett, the average stock pick inside The Richmond Club is up 1,301% vs. just 153% for the S&P.
This is your opportunity to become part of an exclusive membership led by the Richmond Club that has seen an average of 18.26 % gains over the past 15 years!